Formation and Resolution of Pial Microvascular Thrombosis in a Mouse Model of Thrombotic Thrombocytopenic Purpura

Arterioscler Thromb Vasc Biol. 2019 Sep;39(9):1817-1830. doi: 10.1161/ATVBAHA.119.312848. Epub 2019 Jul 25.

Abstract

Objective: Microvascular thrombosis is the hallmark pathology of thrombotic thrombocytopenic purpura (TTP), a rare life-threatening disease. Neurological dysfunction is present in over 90% of patients with TTP, and TTP can cause long-lasting neurological damage or death. However, the pathophysiology of microvascular thrombosis in the brain is not well studied to date. Here, we investigate the formation and resolution of thrombosis in pial microvessels. Approach and Results: Using a cranial intravital microscopy in well-established mouse models of congenital TTP induced by infusion of recombinant VWF (von Willebrand factor), we found that soluble VWF, at high concentration, adheres to the endothelium of the vessel wall, self-associates, and initiates platelet adhesion resulting in the formation of pial microvascular thrombosis in ADAMTS13-/- (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13) mice. Importantly, VWF-mediated pial microvascular thrombosis occurred without vascular injury to the brain, and thrombi consisted of resting platelets adhered onto ultra-large VWF without fibrin in the brain in rVWF (recombinant VWF) challenged ADAMTS13-/- mice. Prophylactic treatment with recombinant ADAMTS13 (BAX930) effectively prevented the onset of the VWF-mediated microvascular thrombosis and therapeutic treatment with BAX930 acutely resolved the preexisting or growing thrombi in the brain of ADAMTS13-/- mice after rVWF challenge. The absence of platelet activation and fibrin formation within VWF-mediated thrombi and efficacy of BAX930 was confirmed with an endothelial-driven VWF-mediated microvascular thrombosis model in mice.

Conclusions: Our results provide important insight into the initiation and development of microvascular thrombi in mouse models that mimics TTP and indicate that rADAMTS13 could be an effective interventional therapy for microvascular thrombosis, the hallmark pathology in TTP.

Keywords: blood platelets; fibrin; platelet aggregation; thrombosis; von Willebrand factor.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • ADAMTS13 Protein / pharmacology
  • ADAMTS13 Protein / physiology
  • Animals
  • Disease Models, Animal
  • Endothelial Cells / physiology
  • Female
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Pia Mater / blood supply*
  • Platelet Activation
  • Platelet Adhesiveness
  • Purpura, Thrombotic Thrombocytopenic / complications*
  • Thrombosis / etiology*
  • Thrombosis / therapy
  • von Willebrand Factor / physiology

Substances

  • von Willebrand Factor
  • ADAMTS13 protein, mouse
  • ADAMTS13 Protein
  • ADAMTS13 protein, human